Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Saw palmetto

This article was originally published in The Tan Sheet

Executive Summary

Patients treated with botanical for six months had 32% decrease in dihydrotestosterone (DHT), a hormone associated with benign prostatic hyperplasia, researchers report in June Urology. Leonard Marks, UCLA School of Medicine, et al., randomized 44 men with symptomatic BPH to either 320 mg/day saw palmetto or placebo. Researchers took right and left mid-saggittal biopsy cores from each patient at baseline and after six months. Ongoing randomized, placebo-controlled trial funded by Urological Sciences Research Foundation and Alticor division Nutriline
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS092663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel